Trial Profile

SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Upadacitinib (Primary)
Indications Systemic lupus erythematosus
Focus Registrational; Therapeutic Use
Acronyms SELECT-SLE
Sponsors AbbVie

Most Recent Events

14 Feb 2025 Planned primary completion date changed from 1 Oct 2026 to 1 Dec 2026.
26 Nov 2024 Planned End Date changed from 31 Oct 2027 to 1 Oct 2027.
26 Nov 2024 Planned primary completion date changed from 2 Oct 2026 to 1 Oct 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com